Skip to main content
Premium Trial:

Request an Annual Quote

Targeted Genetics Stock Delisted from Nasdaq

Premium

Targeted Genetics last week said that it has received written notice from the Nasdaq Stock Market that trading of its common stock has been suspended and that the exchange has delisted the shares.

Targeted Genetics added that it does not plan to appeal the ruling. Its common stock is now traded on the Over-The-Counter Bulletin Board.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.